DuraSorb Monofilament Mesh. Credit: Business Wire.

US medical technology company Surgical Innovation Associates (SIA) has secured CE Mark approval for its absorbable mesh, called DuraSorb.

The mesh offers mechanical support and scaffolding during the early months of wound healing and scar formation. It is gradually absorbed into the body in one year, leaving the patient free of foreign material.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The CE mark approval enables DuraSorb to be used for reconstructive and aesthetic purposes, including abdominal hernia prophylaxis, breast tissue support, and prosthetic breast support.

SIA noted that its technology adds great value in European hospital systems, as it offers a vital alternative to biologic meshes or permanent synthetic meshes.

Surgeons often try to avoid permanent mesh products, while human or animal-based biologic meshes are generally scarce due to safety concerns and high costs.

SIA president and CEO Dr Alexei Mlodinow said: “It is important that we expand access to our products for plastic and reconstructive surgeons and their patients beyond our own borders here in the US.

“We are excited to work with one of several potential partners across the pond to introduce DuraSorb in Europe and, in the future, other markets.”

SIA’s absorbable mesh has been designed by surgeons, textile experts and polymer scientists.

It received initial 510(k) clearance from the Food and Drug Administration (FDA) for soft tissue support in 2018. Last year, the product was used clinically within a post-market registry.

The company began the US commercial efforts for DuraSorb earlier this year.

Currently, no mesh product has approval from the US FDA for any breast procedure.